Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 154
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 1  |  Page : 1-6

Comparison of survival between hodgkin and non-hodgkin lymphoma after autologous stem cell transplantation


1 Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Bone Marrow Transplantation Ward, (Ayatollah) Taleghani Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Internal Medicine, School of Medicine, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute; Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7 Department of Biostatistics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khouzestan, Iran
8 Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Correspondence Address:
Tina Vosoughi
Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ccij.ccij_112_19

Rights and Permissions

Background: Autologous stem cell transplantation (ASCT) is a treatment modality for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients with increasingly usage worldwide. Materials and Methods: One hundred and forty-one patients (96 patients with HL and 45 patients with NHL) who underwent ASCT were followed. We used 3-year overall survival (OS) and 3-year progression-free survival (PFS) to evaluate the survival rates. Results: Comparison of 3-year OS and PFS between HL and NHL had no statistically significant difference (OS: 82% vs. 70.2%,P = 0.07 and PFS: 72.8% vs. 59.6%,P = 0.46). 3-year OS in HL with CR was, however, statistically better than NHL (91% vs. 70.4%,P = 0.007) and 3-year OS in males with HL was statistically better than males with NHL (83.2% vs. 66.7%,P = 0.047). Moreover, 3-year OS and PFS in HL with three or more chemotherapy lines before transplantation were better than NHL with this condition (3-year OS: 72.8% vs. 44%,P = 0.01 and 3-year PFS: 58.1% vs. 33.1%,P = 0.016). Conclusion: Our purpose was to compare the survival rates in two groups of NHL and HL patients after ASCT. Patients with HL generally showed better OS and PFS after ASCT in comparison to patients with NHL, but statistically significant differences were seen only in few comparisons, requiring more studies to be carried out.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed476    
    Printed30    
    Emailed0    
    PDF Downloaded2    
    Comments [Add]    

Recommend this journal